Agios Pharmaceuticals, Inc. Class Action Lawsuit - AGIO

The filed complaint alleges that Agios Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease. While the trial met one of its primary endpoints, it failed to achieve in the other, falling shy of a statistically significant improvement in annualized rate of pain (“pain crises”). Additionally, the “key secondary endpoint of change from baseline in PROMIS Fatigue was not met.” Following this news, Agios’ stock price fell by $22.33 per share to open at $23.16 per share.

In order to be eligible to join the AGIO class action lawsuit, you must have incurred a loss on shares of Agios Pharmaceuticals, Inc. purchased during the class period listed above.